PHARMARON Aktie

 

G Sachs published a research report stating that PHARMARON (03759.HK)'s 2Q revenue grew 20.2% YoY, mainly driven by continued strength in its CDMO business. Adjusted net profit margin improved to 12.5% from 12.2% in the same period last year and 11.4% in 1Q26. Among them, margins for the CDMO and clinical development businesses ......

Daiwa said in a research report that PHARMARON (03759.HK)'s interim results were broadly in line with its earlier profit alert. Revenue increased 17.9% YoY to RMB7.6 billion, in line with the profit alert and reaching the upper end of the group's original guidance of 12% to 18% growth. Adjusted non-IFRS net profit rose 20.3% YoY......

BofAS published a research report stating that PHARMARON (03759.HK)'s revenue for 1H26 increased 17.9% YoY to RMB7.6 billion, with all business segments recording growth. Among them, laboratory services revenue rose 13.7% YoY, CDMO revenue increased 32.8% YoY, and clinical development revenue grew 13.8% YoY. CDMO gross margin ex......

M Stanley issued a report stating that after PHARMARON (03759.HK) announced its 1H26 results, the broker raised its 2026-2030 forecasts by 1-6% to reflect higher revenue assumptions, management's raised guidance, and better working capital efficiency. The TP was raised from HKD31 to HKD35.6. The rating was maintained at "Overwei......

PHARMARON (03759.HK) announced its interim results for the six months ended June 2026. Revenue reached RMB7.595 billion, up 17.9% YoY. Gross profit was RMB2.475 billion, increasing 13.9%. Net profit amounted to RMB750 million, up 7%, with EPS at RMB0.4138. No dividend was declared. (d)~AASTOCKS Financial NewsWebsite: www.aastock......

Nomura published a research report forecasting that PHARMARON (03759.HK)'s 2Q26 revenue will grow 19.4% YoY to about RMB4 billion. Among them, laboratory services and chemistry, manufacturing and controls services are expected to increase 20% and 25% YoY respectively. Driven by a higher contribution from high-margin laboratory s......

HSBC Global Investment Research issued a research report saying that PHARMARON (03759.HK)'s positive profit alert for the interim period showed revenue growth of 16% to 19% YoY during the period, broadly in line with the broker's expectations. Net profit increased 4% to 10% YoY, slightly below expectations, mainly due to a great......

PHARMARON (03759.HK) issued a positive profit alert, expecting interim revenue for the period ended end-Jun this year to reach approximately RMB7.472 billion to RMB7.665 billion, up 16% to 19% YoY. Net profit is expected to be approximately RMB729 million to RMB772 million, up 4% to 10% YoY. Net profit after deducting non-recurr......

Daiwa issued a research report initiating coverage on PHARMARON (03759.HK) H shares with a Buy rating and a TP of HKD25.5.The broker believes PHARMARON will benefit from the recovery in global biopharmaceutical financing and sustained outsourcing demand from multinational pharmaceutical and biotechnology clients. The company's l......

BOCI issued a report stating that PHARMARON (03759.HK) recorded revenue of RMB3.58 billion in 1Q26, up 15.5% YoY, while adjusted net profit increased 16.2% YoY. Newly signed orders rose by more than 30% YoY, of which laboratory services grew by over 20% and small-molecule CDMO expanded by more than 50%. Management maintained its......

CICC said in a research report that PHARMARON (03759.HK) recorded revenue of RMB3.578 billion in 1Q26, up 15.48% YoY, while net profit attributable to shareholders reached RMB335 million, up 9.75% YoY. Profitability remained resilient and slightly exceeded the expectations of the broker and the market. New orders signed in 1Q in......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Morgan Stanley issued a research report updating the risk-reward profile of PHARMARON (03759.HK). The broker raised its target price from HKD31 to HKD31.5 and maintained an Overweight rating. In response to the groups 2025 results, the bank lifted its earnings forecasts for 2026 to 2030 by less than 1% to 3% to reflect higher r......

PHARMARON (03759.HK) announced its results for the fiscal year 2025, reporting a revenue of RMB14.095 billion, up 14.8% year-on-year. The gross profit was RMB4.857 billion, an increase of 17.1%. The company recorded a net profit of RMB1.664 billion, a decline of 7.2%, with earnings per share of 94.43 cents. The final dividend re......

PHARMARON (03759.HK) surged 12.6% to $20.94 in the early session of Hong Kong equity market, and peaked at $21.06 during the intraday trading session. The Company announced a production cooperation agreement with Eli Lilly and Company (LLY.US) for the first registered oral small-molecule GLP-1 receptor agonist, Orforglipron, acc......

As AI technology continues to develop, investors are shifting their focus from "AI enabling industries" to "AI disintermediating middlemen", CLSA said in a research report. For CRO/ CDMO, AI is expected to have a clearer net positive for integrated CRDMO platforms. In contrast, the internal adoption of AI by ......

Citi has published a research report initiating a 90-day positive catalyst watch on PHARMARON (03759.HK). The primary catalysts include the group's upcoming announcement of last year's full-year results and accelerated order growth, leading to more optimistic guidance for this year.The broker has given PHARMARON a Buy ra......

PHARMARON (03759.HK) opened down 3.37% today, bottoming at $23.02. It last printed at $24, down 3.77%, on volume of 6.4042 million shares and turnover of $152 million.The company had earlier announced a placement of nearly 58.4408 million new H shares at an 8.5% discount, which was expected to raise nearly $1.32 billion in net p......

PHARMARON (03759.HK) announced plans to place around 58.4408 million new H-shares (about 3.19% of the enlarged issued share capital and around 16.57% of the total issued H-shares) at a price of HKD22.82 per share, about an 8.5% discount to yesterday's (14th) closing price.The company expects the total and net proceeds from t......

To Further Enhance Structure-Based Drug Discovery and Protein Science Service Capabilities​​BEIJING--(BUSINESS WIRE)--Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (hereinafter referred to as “Pharmaron” and the “Company”) today announced that it has entered into a definitive Share Purchase Agreement to acquire 82.54% equity interest of Biortus Biosciences Co., Ltd. and its affiliates (hereinafter referred to as "Biortus"). The transaction is expected to close upon the satisfaction of customary closing conditions. This transaction will significantly enhance the Company's technological platform and service capabilities in structural biology, complex protein production and analysis and further strengthen the Company's end-to-end, fully integrated, multi-modality services platform with global footprints to better serve global biopharmaceutical clients. Biortus is a leading CRO in structural biology. With comprehensive capabilities in gene to protein to structure, Bior...